|
1
|
Ebneter A and Zinkernagel MS: Novelties in
diabetic retinopathy. Endocr Dev. 31:84–96. 2016.PubMed/NCBI
|
|
2
|
Tarr JM, Kaul K, Chopra M, Kohner EM and
Chibber R: Pathophysiology of diabetic retinopathy. ISRN
Ophthalmol. 2013:3435602013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ahsan H: Diabetic retinopathy-biomolecules
and multiple pathophysiology. Diabetes Metab Syndr. 9:51–54. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cheung N, Mitchell P and Wong TY: Diabetic
retinopathy. Lancet. 376:124–136. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tang J and Kern TS: Inflammation in
diabetic retinopathy. Prog Retin Eye Res. 30:343–358. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hsu H and Viney JL: The tale of TL1A in
inflammation. Mucosal Immunol. 4:368–370. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang Z and Li LY: TNFSF15 Modulates
neovascularization and inflammation. Cancer Microenviron.
5:237–247. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sethi G, Sung B and Aggarwal BB:
Therapeutic potential of VEGI/TL1A in autoimmunity and cancer. Adv
Exp Med Biol. 647:207–215. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chew LJ, Pan H, Yu J, Tian S, Huang WQ,
Zhang JY, Pang S and Li LY: A novel secreted splice variant of
vascular endothelial cell growth inhibitor. FASEB J. 16:742–744.
2002.PubMed/NCBI
|
|
10
|
Parr C, Gan CH, Watkins G and Jiang WG:
Reduced vascular endothelial growth inhibitor (VEGI) expression is
associated with poor prognosis in breast cancer patients.
Angiogenesis. 9:73–81. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yu J, Tian S, Metheny-Barlow L, Chew LJ,
Hayes AJ, Pan H, Yu GL and Li LY: Modulation of endothelial cell
growth arrest and apoptosis by vascular endothelial growth
inhibitor. Circ Res. 89:1161–1167. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Qi JW, Qin TT, Xu LX, Zhang K, Yang GL, Li
J, Xiao HY, Zhang ZS and Li LY: TNFSF15 inhibits vasculogenesis by
regulating relative levels of membrane-bound and soluble isoforms
of VEGF receptor 1. Proc Natl Acad Sci USA. 110:13863–13868. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Stefanini FR, Arevalo JF and Maia M:
Bevacizumab for the management of diabetic macular edema. World J
Diabetes. 4:19–26. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gupta N, Mansoor S, Sharma A, Sapkal A,
Sheth J, Falatoonzadeh P, Kuppermann B and Kenney M: Diabetic
retinopathy and VEGF. Open Ophthalmol J. 7:4–10. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ho AC, Scott IU, Kim SJ, Brown GC, Brown
MM, Ip MS and Recchia FM: Anti-vascular endothelial growth factor
pharmacotherapy for diabetic macular edema: A report by the
american academy of ophthalmology. Ophthalmology. 119:2179–2188.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rao RC and Dlouhy BJ: Diabetic
retinopathy. N Engl J Med. 367:1842012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Deng W, Gu X, Lu Y, Gu C, Zheng Y, Zhang
Z, Chen L, Yao Z and Li LY: Down-modulation of TNFSF15 in ovarian
cancer by VEGF and MCP-1 is a pre-requisite for tumor
neovascularization. Angiogenesis. 15:71–85. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kim S and Zhang L: Identification of
naturally secreted soluble form of TL1A, a TNF-like cytokine. J
Immunol Methods. 298:1–8. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kaul K, Hodgkinson A, Tarr JM, Kohner EM
and Chibber R: Is inflammation a common retinal-renal-nerve
pathogenic link in diabetes? Curr Diabetes Rev. 6:294–303. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Krady JK, Basu A, Allen CM, Xu Y, LaNoue
KF, Gardner TW and Levison SW: Minocycline reduces proinflammatory
cytokine expression, microglial activation and caspase-3 activation
in a rodent model of diabetic retinopathy. Diabetes. 54:1559–1565.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Koleva-Georgieva DN, Sivkova NP and
Terzieva D: Serum inflammatory cytokines IL-1beta, IL-6, TNF-alpha
and VEGF have influence on the development of diabetic retinopathy.
Folia Med (Plovdiv). 53:44–50. 2011.PubMed/NCBI
|
|
22
|
National Research Council (US) Committee
for the Update of the Guide for the Care and Use of Laboratory
Animals, . Guide for the Care and Use of Laboratory Animals. 8th
edition. National Academies Press; Washington (DC): 2011,
PubMed/NCBI
|
|
23
|
Zheng H, Zhang Z, Luo N, Liu Y, Chen Q and
Yan H: Increased Th17 cells and IL17 in rats with traumatic optic
neuropathy. Mol Med Rep. 10:1954–1958. 2014.PubMed/NCBI
|
|
24
|
Wang J, Chen S, Jiang F, You C, Mao C, Yu
J, Han J, Zhang Z and Yan H: Vitreous and plasma VEGF levels as
predictive factors in the progression of proliferative diabetic
retinopathy after vitrectomy. PLoS One. 9:e1105312014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Antcliff RJ and Marshall J: The
pathogenesis of edema in diabetic maculopathy. Semin Ophthalmol.
14:223–232. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhai Y, Ni J, Jiang GW, Lu J, Xing L,
Lincoln C, Carter KC, Janat F, Kozak D, Xu S, et al: VEGI, a novel
cytokine of the tumor necrosis factor family, is an angiogenesis
inhibitor that suppresses the growth of colon carcinomas in vivo.
FASEB J. 13:181–189. 1999.PubMed/NCBI
|
|
27
|
Zhai Y, Yu J, Iruela-Arispe L, Huang WQ,
Wang Z, Hayes AJ, Lu J, Jiang G, Rojas L, Lippman ME, et al:
Inhibition of angiogenesis and breast cancer xenograft tumor growth
by VEGI, a novel cytokine of the TNF superfamily. Int J Cancer.
82:131–136. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hou W, Medynski D, Wu S, Lin X and Li LY:
VEGI-192, a new isoform of TNFSF15, specifically eliminates tumor
vascular endothelial cells and suppresses tumor growth. Clin Cancer
Res. 11:5595–5602. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Penn JS, Madan A, Caldwell RB, Bartoli M,
Caldwell RW and Hartnett ME: Vascular endothelial growth factor in
eye disease. Prog Retin Eye Res. 27:331–371. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zeng HY, Green WR and Tso MO: Microglial
activation in human diabetic retinopathy. Arch Ophthalmol.
126:227–232. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wilkinson-Berka JL, Tan G, Jaworski K and
Miller AG: Identification of a retinal aldosterone system and the
protective effects of mineralocorticoid receptor antagonism on
retinal vascular pathology. Circ Res. 104:124–133. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Huang H, Gandhi JK, Zhong X, Wei Y, Gong
J, Duh EJ and Vinores SA: TNFalpha is required for late BRB
breakdown in diabetic retinopathy and its inhibition prevents
leukostasis and protects vessels and neurons from apoptosis. Invest
Ophthalmol Vis Sci. 52:1336–1344. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Burgós R, Simo R, Audí L, Mateo C, Mesa J,
García-Ramírez M and Carrascosa A: Vitreous levels of vascular
endothelial growth factor are not influenced by its serum
concentrations in diabetic retinopathy. Diabetologia. 40:1107–1109.
1997. View Article : Google Scholar : PubMed/NCBI
|
